TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15217515

Group type: EXPERIMENTAL
Intervention: Lymphatic chemotherapy (LC) - subcutaneous injection of 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (VC) - intravenous administration of 20 mg of aqueous carboplatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lymph node metastasis
Number of subjects: 60
Study: 11231856

Group type: EXPERIMENTAL
Intervention: Steroid group (500 mg of methylprednisolone administered intravenously 2 hours before surgery)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 9670258

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) with concomitant chemotherapy (5-FU, leucovorin)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT)
Number of subjects: 63
Study: 7758398

Group type: EXPERIMENTAL
Intervention: L-carnitine (4 g or 2 g) with 10% or 5% glucose infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10% or 5% glucose infusion without L-carnitine)
Number of subjects: 60
Study: 2455778

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with vinblastine for 6 months
Number of subjects: 253

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Overall treatment (cisplatin, vinblastine, and bleomycin)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Bleomycin pulmonary toxicity
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Myelosuppression
Number of subjects: 253
Study: 30799192

Group type: EXPERIMENTAL
Intervention: Serum albumin levels <51.4 g/L
Number of subjects: 12621

Group type: EXPERIMENTAL
Intervention: Serum albumin levels ≥51.4 g/L
Number of subjects: 12621

Group type: EXPERIMENTAL
Intervention: Serum albumin levels <51.4 g/L without proteinuria
Number of subjects: 12621
Study: 30119072

Group type: EXPERIMENTAL
Intervention: Statistical methods used in trials
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Statistical methodology
Number of subjects: 116
Study: 28600024

Group type: EXPERIMENTAL
Intervention: Cilostazol plus aspirin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 53
Study: 25132320

Group type: EXPERIMENTAL
Intervention: Dexcom®G4 Platinum (DG4P)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Medtronic Paradigm Veo Enlite system (ENL)
Number of subjects: 24
Study: 24189352

Group type: EXPERIMENTAL
Intervention: OS‐1(®)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pocari Sweat(®)
Number of subjects: 10
Study: 21386732

Group type: EXPERIMENTAL
Intervention: Balance Training (BT) for 4 weeks, 3 times per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 19441668

Group type: EXPERIMENTAL
Intervention: Escitalopram (n=51, 10-20 mg/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nortriptyline (n=39, 75-150 mg/day)
Number of subjects: 90
Study: 16687967

Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ
Number of subjects: 872

Group type: COMPARATOR
Intervention: Amlodipine plus HCTZ
Number of subjects: 872
Study: 14728846

Group type: EXPERIMENTAL
Intervention: Combination of metformin and compound cyproterone acetate (CPA) (group A3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metformin alone (group A2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CPA alone (group A1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of metformin and CPA (group A3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (non-PCOS infertility patients, group B)
Number of subjects: 45
Study: 10775075

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) therapy
Number of subjects: 18
Study: 8839730

Group type: EXPERIMENTAL
Intervention: Reformulated Oka strain varicella vaccine
Number of subjects: 191
Study: 1727744

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 6695658

Group type: EXPERIMENTAL
Intervention: Verapamil, 7.5 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31665017

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study: 30037480

Group type: EXPERIMENTAL
Intervention: Reminder letters sent to parents or guardians of eligible adolescents due for the first dose of HPV vaccine.
Number of subjects: 81558

Group type: COMPARATOR
Intervention: Control group (no reminder letters sent until December 8, 2015).
Number of subjects: 81558
Study: 26995797

Group type: EXPERIMENTAL
Intervention: Randomized, comparative local anesthetic blocks
Number of subjects: 4

Group type: COMPARATOR
Intervention: Randomized, placebo-controlled blocks
Number of subjects: 4
Study: 24905296

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 6 months
Number of subjects: 48
Study: 22920048

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40 mg/25 mg
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg daily to OM 40 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 176
Study: 20519552

Group type: EXPERIMENTAL
Intervention: PNU-288034 coadministered with probenecid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PNU-288034 coadministered with cimetidine
Number of subjects: 0
Study: 17602170

Group type: EXPERIMENTAL
Intervention: Blueberry/apple juice providing 97 mg quercetin and 16 mg ascorbic acid a day
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Blueberry/apple juice intervention
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cyp1B1 5 variant genotype
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: COMT variants
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: GSTT1 variants
Number of subjects: 168
Study: 15074091

Group type: EXPERIMENTAL
Intervention: Pushen capsule (PSC) (4 capsules, tid)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Zhibituo tablet (3 tablets, tid)
Number of subjects: 240
Study: 11677003

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg, administered three times daily for 12 months)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg)
Number of subjects: 84
Study: 9704262

Group type: EXPERIMENTAL
Intervention: Attending to red checks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attending to blue checks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attended stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unattended stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer-latency attention-sensitive components
Number of subjects: 0
Study: 8124798

Group type: EXPERIMENTAL
Intervention: Prolonged dilatations (15 minutes)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Standard dilatations (1 minute)
Number of subjects: 478
Study: 2768768

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 101

Group type: COMPARATOR
Intervention: Yoga and Flexibility
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 101
Study: 334220

Group type: EXPERIMENTAL
Intervention: Nomifensine 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nomifensine 50 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30606789

Group type: EXPERIMENTAL
Intervention: Warfarin (18 months treatment after initial 6 months)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (18 months treatment after initial 6 months)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Warfarin (42 months total follow-up)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (42 months total follow-up)
Number of subjects: 104
Study: 29854140

Group type: EXPERIMENTAL
Intervention: CDS program for BMI screening and follow-up
Number of subjects: 33945
Study: 27429204

Group type: EXPERIMENTAL
Intervention: BCG vaccination within 7 days of birth
Number of subjects: 4224

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4224

Group type: EXPERIMENTAL
Intervention: BCG vaccination within 7 days of birth (in children of BCG-vaccinated mothers)
Number of subjects: 4224
Study: 24613094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Estradiol ≥30 ng/mL with percent mean body weight
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Leptin, cortisol, and mental health changes
Number of subjects: 37
Study: 22703475

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 756

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 756
Study: 19148403

Group type: EXPERIMENTAL
Intervention: Occlusal splints fabricated in maximum intercuspation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occlusal splints fabricated in centric relation
Number of subjects: 20
Study: 17724676

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 12484

Group type: COMPARATOR
Intervention: Conventional Papanicolaou (Pap) smear
Number of subjects: 12484
Study: 16086878

Group type: EXPERIMENTAL
Intervention: TP group (docetaxol plus cisplatin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: GP group (gemzar plus cisplatin)
Number of subjects: 43
Study: 12411834

Group type: EXPERIMENTAL
Intervention: I NNC 13‐8241
Number of subjects: 19
Study: 10572333

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (specific type not mentioned)
Number of subjects: 118
Study: 7479228

Group type: EXPERIMENTAL
Intervention: i.v. injection of heparin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 1980415

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Promazin (1.0 mg/kg)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Promethazin (1.0 mg/kg)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Chlorphenaethazin (1.0 mg/kg)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 206
Study: 6992760

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo influences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial treatment factors (sex, social class, optimism about therapist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural course of migraine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of improvement during treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of improvement at end of trial
Number of subjects: 0
Study: 31124401

Group type: EXPERIMENTAL
Intervention: SMS or voice call reminders at 48 and 24 hours before the postnatal appointment
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual notification of appointments provided by health professionals at discharge
Number of subjects: 350
Study: 27658914

Group type: EXPERIMENTAL
Intervention: Being Responsible for Ourselves (BRO) physical‐activity intervention consisting of three 90‐min one‐on‐one sessions
Number of subjects: 595

Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 595
Study: 25328079

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metformin (750 mg)
Number of subjects: 25
Study: 24942407

Group type: EXPERIMENTAL
Intervention: Cilostazol (100mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clopidogrel (75mg daily)
Number of subjects: 100
Study: 22714065

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery clipping and myomectomy (experimental group)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy only (control group)
Number of subjects: 166
Study: 21147691

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg intravenous every 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 68
Study: 17991545

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg/day for 120 days) plus surgery
Number of subjects: 119

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 119
Study: 16296363

Group type: EXPERIMENTAL
Intervention: Clonidine 3‐4 microg x kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam 0.04‐0.05 mg x kg(‐1)
Number of subjects: 40
Study: 11911994

Group type: EXPERIMENTAL
Intervention: Glyceryltrinitrate (GTN) + Capsaicin cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Capsaicin cream alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GTN alone
Number of subjects: 40
Study: 9391198

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional appendectomy (CA)
Number of subjects: 82
Study: 8903900

Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia (BPD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pre-term (PT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BPD boys
Number of subjects: 24
Study: 1708910

Group type: EXPERIMENTAL
Intervention: CHOP-Bleo
Number of subjects: 83

Group type: COMPARATOR
Intervention: m-BACOD
Number of subjects: 83
Study: 7432958

Group type: EXPERIMENTAL
Intervention: Process Association Tests of Addiction
Number of subjects: 47
Study: 31160237

Group type: EXPERIMENTAL
Intervention: Carfilzomib (56 mg/m2) and Dexamethasone (Kd56)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bortezomib and Dexamethasone (Vd)
Number of subjects: 0
Study: 28973620

Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Clinically guided warfarin dosing
Number of subjects: 1650
Study: 26025335

Group type: EXPERIMENTAL
Intervention: S + V (cycle sprints plus an aggressive video)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: V + S (aggressive video plus cycle sprints)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 24
Study: 23537721

Group type: EXPERIMENTAL
Intervention: rIX-FP (25 IU/kg) on-demand therapy for 20 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: rIX-FP (25 IU/kg) weekly prophylaxis for up to 44 weeks
Number of subjects: 17
Study: 21147514

Group type: EXPERIMENTAL
Intervention: 70 Gy radiotherapy
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: 80 Gy radiotherapy
Number of subjects: 306

Group type: COMPARATOR
Intervention: Quality of life assessment
Number of subjects: 306
Study: 19950570

Group type: EXPERIMENTAL
Intervention: TAM sequential (TAM_SEQ)
Number of subjects: 163

Group type: COMPARATOR
Intervention: TAM concurrent (TAM_CON)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: AI sequential (AI_SEQ)
Number of subjects: 163

Group type: COMPARATOR
Intervention: AI concurrent (AI_CON)
Number of subjects: 163
Study: 17300863

Group type: EXPERIMENTAL
Intervention: Interferon-beta(1a) (Rebif, Serono) subcutaneous injections three times a week (group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Not receiving disease-modifying treatment (group B)
Number of subjects: 25
Study: 16437737

Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qigong
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 12554614

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sober condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure
Number of subjects: 64
Study: 10983671

Group type: EXPERIMENTAL
Intervention: E/A ratio
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atrial to total mitral annulus motion (AC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maximal longitudinal LV relaxation velocity (RVm)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 8857018

Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 60
Study: 1298048

Group type: EXPERIMENTAL
Intervention: Repeated injections of ranitidine, 50 mg every 6 h (group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine, 50-mg bolus followed by 0.125 mg/kg/h (group B)
Number of subjects: 18
Study: 6326014

Group type: EXPERIMENTAL
Intervention: Lonidamine alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lonidamine in combination with other anticancer agents
Number of subjects: 16
Study: 31832719

Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette gum, 6mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study: 31145689

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg) with piperine (5 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 28462892

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0mg
Number of subjects: 4577

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4577
Study: 25316484

Group type: EXPERIMENTAL
Intervention: Nonobese women
Number of subjects: 182

Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study: 23311678

Group type: EXPERIMENTAL
Intervention: Gamified activation method (6-month intervention)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1500
Study: 21844746

Group type: EXPERIMENTAL
Intervention: Recurrent pelvic inflammatory disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent sexually transmitted infection
Number of subjects: 0
Study: 18488813

Group type: EXPERIMENTAL
Intervention: Adcef Suspension (125 mg/5 ml cefdinir)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (125 mg/5 ml cefdinir)
Number of subjects: 24
Study: 17109346

Group type: EXPERIMENTAL
Intervention: Attenuated rotavirus vaccine candidate 89-12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotarix vaccine developed from attenuated 89-12
Number of subjects: 0
Study: 15235312

Group type: EXPERIMENTAL
Intervention: Valtrex treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 11765590

Group type: EXPERIMENTAL
Intervention: lysine clonixinate (125 mg five times a day for 3 days before and 13 days after ingestion of a single dose of phenprocoumon)
Number of subjects: 12

Group type: COMPARATOR
Intervention: phenprocoumon (18 mg)
Number of subjects: 12
Study: 9253919

Group type: EXPERIMENTAL
Intervention: Closed bone-grafting technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open bone-grafting technique
Number of subjects: 40
Study: 8515822

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg s.c.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (physiological saline s.c.)
Number of subjects: 16
Study: 3103932

Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5-FU plus BCNU
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with SD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with PD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with unmeasurable disease
Number of subjects: 46
Study: 29436564

Group type: EXPERIMENTAL
Intervention: Celery leaf extract (250 mg, 3 times per day for 12 days)
Number of subjects: 16
Study: 27693990

Group type: EXPERIMENTAL
Intervention: Patellar Taping (based in McConnell)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (vertical taping on patella without any stretching of lateral structures of the knee)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Patellar Taping and Placebo)
Number of subjects: 40
Study: 25325506

Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) recruitment from sleep clinics
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) recruitment from cardiology clinics
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mail-based recruitment (MBR) from cardiology clinics
Number of subjects: 148
Study: 23389964

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for OCD
Number of subjects: 46

Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 46
Study: 20613468

Group type: EXPERIMENTAL
Intervention: Propofol (6 microg/ml) via plasma target‐controlled infusion using the Schnider model
Number of subjects: 16
Study: 19034030

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 16
Study: 16704094

Group type: EXPERIMENTAL
Intervention: 1.1% sodium fluoride and acidulated phosphate gel
Number of subjects: 86

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride in a silica base
Number of subjects: 86
Study: 14517525

Group type: EXPERIMENTAL
Intervention: Full intervention (n=79)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Partial intervention (n=71)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Waiting list control group (n=102)
Number of subjects: 252
Study: 10775074

Group type: EXPERIMENTAL
Intervention: Acyclovir prophylaxis
Number of subjects: 8

Group type: COMPARATOR
Intervention: VZIG prophylaxis alone (Control)
Number of subjects: 8
Study: 8990355

Group type: EXPERIMENTAL
Intervention: MeCsA
Number of subjects: 1097

Group type: COMPARATOR
Intervention: ConCsA
Number of subjects: 1097
Study: 1637603

Group type: EXPERIMENTAL
Intervention: pH-stat group
Number of subjects: 65

Group type: COMPARATOR
Intervention: alpha-stat group
Number of subjects: 65
Study: 6711725

Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet with KCl salt substitute
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet without KCl salt substitute
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 69